Litigation Details for BAUSCH HEALTH COMPANIES INC. v. ACTAVIS LABORATORIES FL, INC. (D.N.J. 2019)

« Back to Dashboard

BAUSCH HEALTH COMPANIES INC. v. ACTAVIS LABORATORIES FL, INC. (D.N.J. 2019)

Docket		Date Filed	2019-06-13
Court	District Court, D. New Jersey	Date Terminated	2021-03-19
Cause	35:271 Patent Infringement	Assigned To	Stanley R. Chesler
Jury Demand	None	Referred To	Cathy L. Waldor
Patents	10,307,417; 8,420,663; 8,524,276; 8,956,651; 9,180,125; 9,314,461; 9,492,445; 9,724,343
Link to Docket	External link to docket

Details for BAUSCH HEALTH COMPANIES INC. v. ACTAVIS LABORATORIES FL, INC. (D.N.J. 2019)

Date Filed	Document No.	Description	Snippet	Link To Document
2019-06-13				External link to document
2019-06-13	1	Complaint	United States Patent No. 10,307,417 (“the ’417 patent”) arising under the United States patent laws, Title… THE PATENT IN SUIT 26. The U.S. Patent and Trademark Office (“PTO”…PTO”) issued the ’417 patent on June 4, 2019. The ’417 patent claims, inter alia, compositions of methylnaltrexone…the ’417 patent and have the right to sue for infringement thereof. A copy of the ’417 patent is attached…Defendants. COMPLAINT FOR PATENT INFRINGEMENT Plaintiffs Bausch Health Companies	External link to document

Bausch Health v. Actavis Laboratories FL: Litigation Summary and Patent Analysis

Last updated: September 28, 2026

Bausch Health Companies Inc. v. Actavis Laboratories FL, Inc., No. 2:19-cv-13722, was an Abbreviated New Drug Application patent case involving Actavis’s proposed generic version of Xifaxan, Bausch’s rifaximin product. The dispute was part of Bausch’s broader effort to protect Xifaxan exclusivity against generic applicants. The case was filed in the U.S. District Court for the District of New Jersey under the Hatch-Waxman framework.

The central commercial issue was whether Actavis could launch a generic rifaximin product before expiration of Bausch’s Orange Book-listed patents covering rifaximin formulations and approved uses.

What drug was at issue in Bausch Health v. Actavis?

The litigation concerned Xifaxan, the brand name for rifaximin, an orally administered rifamycin antibacterial marketed by Bausch’s Salix business.

Xifaxan is approved in the United States for:

Indication	Commercial relevance
Reduction in risk of overt hepatic encephalopathy recurrence in adults	Major chronic-use market
Treatment of irritable bowel syndrome with diarrhea in adults	Major high-volume indication

The 550 mg tablet is used for hepatic encephalopathy and the 550 mg three-times-daily regimen for 14 days is used for IBS-D. Xifaxan has limited systemic absorption, and its commercial value derives from chronic or repeat use rather than a conventional short-course antibiotic market.

Bausch’s litigation strategy relied on patents directed to rifaximin products, pharmaceutical compositions, crystalline or polymorphic forms, and methods of treating gastrointestinal disorders.

What was the legal basis for the case?

Actavis presumably submitted an ANDA seeking FDA approval for a generic rifaximin product. Bausch responded with an infringement action under 35 U.S.C. § 271(e)(2), which treats submission of an ANDA containing a Paragraph IV certification as a technical act of patent infringement.

A Paragraph IV certification asserts that an Orange Book-listed patent is invalid, unenforceable, or not infringed. Filing suit within 45 days of receiving the Paragraph IV notice generally triggers a 30-month stay of FDA approval under 21 U.S.C. § 355(j)(5)(B)(iii).

The case therefore presented two linked questions:

1. Whether Actavis’s proposed rifaximin product would infringe the asserted patents.
2. Whether Actavis could establish that those patents were invalid or unenforceable.

The statutory stay would have delayed FDA approval unless the litigation ended earlier, the court issued a final decision, or the statutory period otherwise expired.

Which patents protected Xifaxan?

Xifaxan’s patent estate included multiple families rather than a single compound patent. The core intellectual-property protection was built around rifaximin formulations, solid-state forms, and approved methods of use.

Important Xifaxan-related patents included:

Patent	General subject matter	Strategic role
U.S. Patent No. 8,309,569	Rifaximin formulation and related product protection	Core product protection
U.S. Patent No. 8,642,573	Rifaximin composition and formulation claims	Additional formulation barrier
U.S. Patent No. 9,421,195	Rifaximin product or solid-state protection	Later-expiring protection
U.S. Patent No. 10,335,462	Rifaximin formulation or manufacturing-related protection	Extended patent coverage
Other listed patents	Method-of-use, formulation, and product claims	Layered Orange Book protection

The exact patents asserted against Actavis must be determined from the operative complaint, infringement contentions, and final docket papers. Patent listings can change over time through delisting, expiration, statutory disclaimers, or Orange Book corrections.

The commercial importance of the later-issued patents was substantial. Earlier Xifaxan patents approached expiration, while later patents could support a later generic launch date if they survived validity and infringement challenges.

What did Bausch need to prove?

Bausch’s infringement case likely depended on the scope of the asserted claims and the composition of Actavis’s ANDA product.

Formulation infringement

Formulation claims can cover combinations of rifaximin with excipients, particle characteristics, dosage-unit composition, dissolution properties, or manufacturing parameters. An ANDA applicant may attempt to avoid infringement by changing excipients or process conditions, but those changes must remain consistent with FDA requirements and the proposed product’s bioequivalence profile.

Method-of-use infringement

Method claims may cover administration of rifaximin for hepatic encephalopathy or IBS-D. Method-of-use claims create a distinct litigation issue because an ANDA applicant can sometimes use a section viii statement to carve out a patented indication.

A carve-out is less effective when:

• The generic label still encourages the patented use.
• The remaining label instructions are difficult to separate from the patented indication.
• Prescribers are likely to use the generic for the patented indication.
• The patented use is embedded in dosing, patient-selection, or safety instructions.

Product-by-process and manufacturing claims

Some rifaximin patents may depend on how the active ingredient or dosage form is made. These claims can be difficult to enforce against a generic applicant if the ANDA does not disclose the complete manufacturing process or if the claim requires a process limitation not reflected in the finished product.

How strong was Bausch’s Xifaxan patent estate?

Bausch’s estate was commercially strong because it used multiple patent categories to extend protection beyond the earliest compound-related patents. Its strength was not uniform across every patent.

Patent category	Relative strength	Main vulnerability
Basic rifaximin composition claims	Moderate to strong historically	Expiration and prior-art attacks
Formulation claims	Stronger where product-specific	Design-around and claim-construction disputes
Polymorph or solid-state claims	Potentially strong	Anticipation, obviousness, and characterization evidence
Method-of-use claims	Valuable for chronic indications	Label carve-outs and divided-use arguments
Manufacturing claims	Variable	Difficulty proving process limitations

The primary risks were obviousness, anticipation, written description, enablement, indefiniteness, and noninfringement based on Actavis’s proposed formulation or manufacturing process.

The estate’s practical value also depended on Orange Book listing discipline. A patent that is technically relevant but not properly listed may not generate the same Paragraph IV litigation leverage or 30-month stay.

What was the Orange Book status of Xifaxan?

Xifaxan was listed in the FDA Orange Book with multiple patents and exclusivity entries. The listed patents extended beyond the earliest Xifaxan approvals and covered product and use claims.

Orange Book-listed patents can create several distinct barriers:

1. A Paragraph IV notice can trigger litigation.
2. A lawsuit can impose the statutory 30-month approval stay.
3. A patent expiration date can determine the earliest lawful commercial launch.
4. A method-of-use patent can remain relevant even after formulation protection expires.
5. A later-listed patent can create a second litigation cycle if an ANDA applicant files a new certification.

Orange Book status should be evaluated by product strength and indication. A patent listed for the 550 mg tablet may not have identical scope against every proposed rifaximin dosage form or use.

When could Actavis launch a generic version?

The likely launch date depended on four variables:

Variable	Effect on launch
Outcome of infringement litigation	A finding of infringement can block approval until patent expiration
Validity of asserted patents	Invalidity can remove the barrier
30-month stay	Can delay FDA approval even before trial resolution
Settlement terms	May authorize an agreed entry date before patent expiration

If Actavis held a first-filed Paragraph IV position, it also could have been eligible for 180-day generic exclusivity under the Hatch-Waxman regime. That status would depend on FDA records and whether other applicants shared or forfeited eligibility.

A settlement could have produced a confidential or partially disclosed entry date. In pharmaceutical patent cases, settlement agreements often include:

• An authorized generic arrangement.
• A license to enter before patent expiration.
• A fixed launch date.
• Restrictions on dosage forms or indications.
• Supply or manufacturing terms.
• Covenants not to sue on specified patents.

The existence and terms of any settlement must be distinguished from a judicial finding on patent validity or infringement.

What was the litigation status?

The case was an ANDA patent action filed in the District of New Jersey in 2019. The docket number identifies the federal action as No. 2:19-cv-13722.

Public docket analysis should separate three possible outcomes:

1. Adjudication: The court reached claim construction, trial, judgment, or appeal.
2. Settlement: The parties resolved the case through a stipulated dismissal or consent judgment.
3. Administrative closure: The case was closed after settlement or another procedural resolution without a merits judgment.

A docket dismissal alone does not establish that Actavis’s patents defenses succeeded. It may reflect a negotiated license or agreed launch date. Likewise, a stipulated judgment may preserve an agreed infringement finding without resolving every validity issue.

The key documents for determining the final result are the amended complaint, Actavis’s Paragraph IV notice, the asserted-patent list, claim-construction orders, dispositive motions, settlement stipulation, consent judgment, and any Federal Circuit appeal.

Did the case affect generic competition?

Yes. The case was part of a broader generic-entry contest surrounding Xifaxan. Other ANDA applicants and patent litigations involving rifaximin created a competitive landscape in which the first approved generic could have a major commercial advantage.

Xifaxan is unusually exposed to generic substitution because:

• It has substantial chronic-use demand in hepatic encephalopathy.
• It has a large IBS-D patient population.
• Its branded price materially exceeds ordinary generic antibiotic pricing.
• Formulation and manufacturing complexity can limit immediate competition.
• Multiple patents may produce staggered entry dates.

The first generic entrant could capture significant volume, particularly in pharmacy and payer channels. Later entrants would likely face rapid price erosion unless patents, exclusivity, supply constraints, or product differentiation limited substitution.

What revenue exposure did Bausch face?

Xifaxan was one of Bausch’s most commercially important products. Generic entry would affect:

• Net sales from the 550 mg tablet.
• Gross margin.
• Chronic hepatic encephalopathy prescriptions.
• IBS-D refill and repeat-use volume.
• Rebates and payer contracting.
• Salix segment earnings.
• Valuation based on expected cash flow duration.

The revenue impact would depend on whether Actavis launched at risk, entered under a settlement license, or remained blocked until the relevant patent expiration dates.

A single generic entrant can reduce net pricing materially, but the initial effect may be moderated by branded-prescription retention, authorized generic supply, payer contracts, and limited substitution for some patients. The impact generally increases as additional generic manufacturers enter.

How does this case compare with other Xifaxan litigation?

The Actavis case should be analyzed as one action in a larger Xifaxan patent program. Bausch also litigated against other generic manufacturers, including cases involving Norwich Pharmaceuticals and additional ANDA applicants.

The Delaware litigation involving Norwich was particularly important because it produced substantive judicial rulings on Xifaxan patent claims and generic-entry issues. The Actavis case may have been resolved on a different procedural track and should not be treated as a merits determination unless the docket contains a final judgment after trial or dispositive motion practice.

Issue	Actavis litigation	Broader Xifaxan program
Defendant	Actavis Laboratories FL, Inc.	Multiple generic applicants
Product	Proposed generic rifaximin	Xifaxan 550 mg and related proposals
Legal framework	Hatch-Waxman Paragraph IV litigation	Parallel ANDA actions
Main risk	Formulation, use, and patent-validity defenses	Coordinated erosion of brand exclusivity
Commercial result	Depends on dismissal, judgment, or settlement	Determines timing and number of generic entrants

What are the principal generic-entry risks?

The main risks to Bausch were:

• A court finding one or more asserted patents invalid.
• A noninfringement ruling based on Actavis’s formulation or manufacturing process.
• A label carve-out that permits approval for an unpatented indication.
• A settlement that permits early entry.
• A later generic obtaining approval after the first entrant establishes substitutability.
• A court narrowing claims through claim construction.
• Patent expiration before final resolution.
• A competing applicant prevailing in separate litigation.

The main risk to Actavis was a launch delay lasting until expiration of enforceable Xifaxan patents. An at-risk launch could expose Actavis to substantial damages, including possible lost-profit or reasonable-royalty claims, depending on the patent and infringement theories.

Key Takeaways

• Bausch Health v. Actavis Laboratories FL, No. 2:19-cv-13722, was a Hatch-Waxman case concerning a proposed generic version of Xifaxan, or rifaximin.
• Bausch’s protection relied on a layered estate covering formulations, solid-state properties, methods of use, and potentially manufacturing-related limitations.
• The commercial dispute centered on whether Actavis could obtain FDA approval and launch before the expiration of enforceable Orange Book-listed patents.
• The case should not be treated as a patent-validity ruling unless the docket shows a merits judgment.
• Any stipulated dismissal or settlement must be analyzed for its agreed launch date, authorized-generic provisions, and scope of released patents.
• Generic entry would expose Bausch’s high-value Salix franchise to price erosion, volume substitution, and reduced long-term cash flow.
• The broader Xifaxan patent program, including other ANDA litigations, was more important to exclusivity than any single defendant action.

FAQs About Bausch Health v. Actavis Laboratories FL

Was Bausch Health v. Actavis a Paragraph IV case?

Yes. The action was an ANDA patent infringement case under the Hatch-Waxman Act and arose from Actavis’s proposed generic rifaximin product.

Did Actavis receive FDA approval for generic Xifaxan?

FDA approval and commercial launch must be evaluated separately. Approval may occur after patent litigation or a statutory stay, while a settlement may impose a later agreed launch date.

Did Bausch sue Actavis over the Xifaxan compound itself?

The litigation involved Bausch’s broader rifaximin patent estate. The asserted claims likely included formulation, product, method-of-use, or related patent claims rather than relying solely on an original compound patent.

Can a generic manufacturer avoid Xifaxan method-of-use patents?

Potentially. An applicant may submit a section viii statement and omit a patented indication, but infringement risk remains if the proposed labeling or marketing encourages the patented use.

What is the investment significance of the case?

The case affected the duration and defensibility of Xifaxan revenue. Its value depends on the final procedural outcome, the enforceable patent expiration dates, the number of competing ANDA applicants, and the terms of any generic-entry settlement.

References

1. U.S. District Court for the District of New Jersey. (2019). Bausch Health Companies Inc. v. Actavis Laboratories FL, Inc., No. 2:19-cv-13722, docket materials.

2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

3. 21 U.S.C. § 355(j). Abbreviated new drug applications and patent certifications.

4. 35 U.S.C. § 271(e)(2). Patent infringement based on submission of an abbreviated new drug application.

5. U.S. Patent and Trademark Office. (n.d.). Patent Center. U.S. Department of Commerce.